++
++
++
++
++
Type 1 and 2 gNETs:
Small type 1 and 2 gNETs: endoscopic resection followed by endoscopic surveillance every 6–12 months, or with observation
Antrectomy reduces serum gastrin levels and may lead to regression of small tumors
Type 2 gNETs with underlying gastrinoma and Zollinger-Ellison syndrome may be treated with somatostatin analog (octreotide) therapy
Patients with tumors > 2 cm in size should undergo endoscopic or surgical resection
Localized sporadic type 3 and 4 gNETs should be treated with partial or total gastrectomy and regional lymphadenectomy
Octreotide may provide symptomatic relief for patients with gNETs that are functional (carcinoid syndrome)
Advanced high-grade gastric neuroendocrine carcinomas are treated in a fashion similar to small cell lung cancers